These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38258529)

  • 1. Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed
    Gupta N; Boodman C; Prayag P; Manesh A; Kumar TP
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):203-209. PubMed ID: 38258529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
    Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
    J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.
    Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.
    Khan S; Das A; Vashisth D; Mishra A; Vidyarthi AJ; Gupta R; Begam NN; Kataria B; Bhatnagar S
    PLoS One; 2024; 19(5):e0303753. PubMed ID: 38758757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
    Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
    Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
    J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
    Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
    Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
    Sree RA; Gupta A; Gupta N; Veturi S; Reddy LSK; Begum M; Shravani E; Challa HR; Reddy SS; Singamsetty A; Arumilli M; Reddy PN; Tirlangi PK
    Infection; 2024 Apr; 52(2):429-437. PubMed ID: 37697224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Features and Outcomes of Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area.
    Falcone M; Giordano C; Leonildi A; Galfo V; Lepore A; Suardi LR; Riccardi N; Barnini S; Tiseo G
    Clin Infect Dis; 2024 May; 78(5):1111-1119. PubMed ID: 38036465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
    Avery LM; Nicolau DP
    Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
    Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
    Aitken SL; Tarrand JJ; Deshpande LM; Tverdek FP; Jones AL; Shelburne SA; Prince RA; Bhatti MM; Rolston KVI; Jones RN; Castanheira M; Chemaly RF
    Clin Infect Dis; 2016 Oct; 63(7):954-958. PubMed ID: 27313265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-β-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.
    Senchyna F; Murugesan K; Rotunno W; Nadimpalli SS; Deresinski S; Banaei N
    Clin Infect Dis; 2024 Jun; 78(6):1425-1428. PubMed ID: 38289725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.